New Delhi, India – 110 016
South Delhi Pharma, New Delhi, India
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.
PARSABIV (etelcalcetide) injection is a prescription medicine. PARSABIV (etelcalcetide) injection is used to treat chronic kidney disease (CKD).
INDICATIONS AND USAGE
Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
DOSAGE FORMS & STRENGTHS
Injection: 2.5 mg/0.5 mL solution in a single-dose vial
Injection: 5 mg/mL solution in a single-dose vial
Injection: 10 mg/2 mL solution in a single-dose vial
Manufactured By: Amgen Inc
Prescribing Information URL: Click Here
South Delhi Pharma facilitate the supply of “PARSABIV (etelcalcetide) injection FDA Approved” medication. Supplied under Named Patient Program to all locations in India and other part of countries. Anti-Cancer drugs is available upon request after fulfilling the legal requirement (if applicable). To get best price share your mobile number and email ID.
Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session. Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.
